Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Billions At Stake As Generic Approvals Open Up Japan Big Sellers

Executive Summary

Japan has approved a new batch of first-time and other generic drugs that will be reimbursed and launched in June, putting at risk several billion dollars’ worth of combined sales of some major branded products.

You may also be interested in...



Jardiance Is The Star Of Boehringer’s Show, But Micardis Drag Spoils The Party

Jardiance growth offsets Micardis woes as the German major updates the industry on its H1.

Sandoz Eyes Doubling Of Japan Business Despite Price Pressures

Sandoz is bullish on the prospects for its Japanese business, helped by an operating environment it sees as favoring generics and biosimilars and despite growing cost control pressures.

ASCO 2020: Positive Early Data For Keytruda/Lenvima In Liver, Kidney Cancer

Partners say they are encouraged by new overall response data from early trials for the two drugs together in kidney and liver cancer, presented to ASCO.

Topics

Related Companies

UsernamePublicRestriction

Register

SC010771

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel